

Autoreactive B Cells in Membranous Nephropathy

NCT04095156

Status	RECRUITING
Sponsor	Mario Negri Institute for Pharmacological Research
Enrollment	86 participants

Key Eligibility Criteria

Inclusion (9)

- Males and females.
 - Adults (> 18 years old).
 - Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practice.
 - Mental state is such that they are able to understand and give valid consent to the study;
 - Written informed consent according to the guidelines of the Declaration of Helsinki.
- ... and 4 more (see full listing online)

Exclusion (3)

- Reasonable possibility of a secondary cause of MN (e.g.systemic lupus erythematosus, active hepatitis B, malignancy, drugs such as gold salts and penicillamine).
- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.
- \- Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Locations (1 total)

Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò", Ranica, BG, Italy